# OnCo record paper-keynote-775-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-775-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-775-nejm-2022" ;
  schema:name "KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer"@en ;
  schema:description "After platinum chemotherapy, the combination of the kinase inhibitor lenvatinib and pembrolizumab lengthened survival compared with doxorubicin or paclitaxel in advanced endometrial cancer, including in the mismatch repair-proficient majority."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-775-nejm-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2108330>, <https://pubmed.ncbi.nlm.nih.gov/35045221/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2108330> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Makker V, Colombo N, Casado Herráez A, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-775/> ;
  onco:journals <https://onco.cc/journals/nejm/> .